Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Novartis will pay $2 billion up front to acquire a drug that could improve upon existing treatments for patients with a particular form of breast cancer.…
Novartis will spend $2 billion upfront to buy a more selective PI3Kalpha inhibitor, intensifying the competition to develop a new wave of breast cancer drugs.…
Why Novartis Is Paying $2B for a Cancer Drug That Hits the Same Target as One of Its Own Products. SNV4818 applies new mutant selective chemistry to more…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Novartis agreed to acquire Pikavation Therapeutics from parent Synnovation Therapeutics for $2B upfront plus up to $1B in milestones. The lead asset SNV4818 is an oral pan-mutant-selective PI3Kalpha inhibitor in Phase 1/2 for breast cancer (~40% of HR+/HER2- patients harbor PIK3CA mutations). Transaction is expected to close in H1 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Pikavation Therapeutics, Inc. (this deal) | 2026 | $3.0B | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2026 deals · Novartis AG deals · Oncology deals